NASDAQ: CTOR
Citius Oncology Inc Stock

$1.20+0.02 (+1.69%)
Updated Feb 10, 2025
CTOR Price
$1.20
Fair Value Price
-$0.42
Market Cap
$85.86M
52 Week Low
$0.85
52 Week High
$49.00
P/E
-3.87x
P/B
1.86x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$21.15M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.83
Operating Cash Flow
$126k
Beta
-1.42
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

CTOR Overview

TenX Keane Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on target businesses operating in Asia, excluding companies located or operating in mainland China, Hong Kong, or Macau. The company was founded in 2021 and is based in New York, New York.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine CTOR's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Value
D
Growth
D
Momentum
B
Sentiment
C
Safety
D
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Pharmaceutical

Industry Rating
B
CTOR
Ranked
#50 of 63

Top Ranked Stocks in Industry

View Top Pharmaceutical Stocks

Be the first to know about important CTOR news, forecast changes, insider trades & much more!

Overview

Due Diligence Score

–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CTOR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CTOR ($1.20) is overvalued by 384.72% relative to our estimate of its Fair Value price of -$0.42 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CTOR ($1.20) is not significantly undervalued (384.72%) relative to our estimate of its Fair Value price of -$0.42 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CTOR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CTOR due diligence checks available for Premium users.

Valuation

CTOR fair value

Fair Value of CTOR stock based on Discounted Cash Flow (DCF)

Price
$1.20
Fair Value
-$0.42
Undervalued by
384.72%
CTOR ($1.20) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CTOR ($1.20) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CTOR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CTOR price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-3.87x
Industry
9.56x
Market
31x

CTOR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.86x
Industry
2.18x
CTOR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CTOR's financial health

Profit margin

Revenue
$0.0
Net Income
-$6.8M
Profit Margin
0%
CTOR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$84.4M
Liabilities
$38.2M
Debt to equity
0.83
CTOR's short-term liabilities ($32.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CTOR's short-term assets ($10.97M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CTOR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$126.4k
Investing
$0.0
Financing
$0.0
CTOR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CTOR vs Pharmaceutical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
CTORC$85.86M+1.69%-3.87x1.86x
ASRTB$78.29M+2.37%-1.86x0.60x
INCRC$77.61M-0.41%-4.40x0.63x
CRDLF$96.17M+1.48%-3.53x12.81x
BGMB$74.14M-2.38%-51.30x1.73x

Citius Oncology Stock FAQ

What is Citius Oncology's quote symbol?

(NASDAQ: CTOR) Citius Oncology trades on the NASDAQ under the ticker symbol CTOR. Citius Oncology stock quotes can also be displayed as NASDAQ: CTOR.

If you're new to stock investing, here's how to buy Citius Oncology stock.

What is the 52 week high and low for Citius Oncology (NASDAQ: CTOR)?

(NASDAQ: CTOR) Citius Oncology's 52-week high was $49.00, and its 52-week low was $0.85. It is currently -97.55% from its 52-week high and 41.18% from its 52-week low.

How much is Citius Oncology stock worth today?

(NASDAQ: CTOR) Citius Oncology currently has 71,552,402 outstanding shares. With Citius Oncology stock trading at $1.20 per share, the total value of Citius Oncology stock (market capitalization) is $85.86M.

Citius Oncology stock was originally listed at a price of $10.03 in Oct 14, 2022. If you had invested in Citius Oncology stock at $10.03, your return over the last 2 years would have been -88.04%, for an annualized return of -65.41% (not including any dividends or dividend reinvestments).

How much is Citius Oncology's stock price per share?

(NASDAQ: CTOR) Citius Oncology stock price per share is $1.20 today (as of Feb 10, 2025).

What is Citius Oncology's Market Cap?

(NASDAQ: CTOR) Citius Oncology's market cap is $85.86M, as of Feb 11, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Citius Oncology's market cap is calculated by multiplying CTOR's current stock price of $1.20 by CTOR's total outstanding shares of 71,552,402.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.